# DLMAI v3.0 — Pillar 7 Corporate & Manufacturing Role Experiment Report

**Document ID:** DLMAI-DOC-v3-P7-ROLE  
**Classification:** Pharmaceutical Competitive Dynamics & Architectural Specification  
**Target Repository:** `e:/DMLIA-Sun pharma/dlmai_complete`  
**Date:** August 2026  

---

## 1. The Core Methodological Dilemma

How should pharmaceutical corporate and manufacturing concentration (derived from the 943k MCA21 registry) be treated in a district market attractiveness index?

Three conceptual hypotheses exist in pharmaceutical commercial strategy:
1. **Hypothesis A (Market Saturation Dampener):** High corporate presence implies heavy local doctor detailing, intense generic substitution, and price erosion. It should serve as a subtractive penalty ($V - \lambda \cdot P7$) to favor underserved territories.
2. **Hypothesis B (Ecosystem Synergies / Positive Driver):** High corporate presence signals mature healthcare supply chains, robust cold-chain logistics, skilled medical talent, and high doctor density. It should serve as an additive positive driver ($V + w \cdot P7$).
3. **Hypothesis C (Strategic 2-Axis Decoupling):** Intrinsic patient clinical demand and corporate manufacturing saturation measure two fundamentally distinct commercial dimensions and should **never be forced into a single scalar number** that obscures strategic clarity.

---

## 2. Quantitative Comparison of P7 Role Formulations

| Formulation Option | Mathematical Formula | Spearman $\rho$ vs Core Demand | Top-10 Rank Preservation | Strategic Utility | Recommendation |
|---|---|---|---|---|---|
| **Option A: Negative Dampener** | $\text{DLMAI} = V - 0.15 \cdot \text{P7}$ | 0.9812 | 100.0% | Penalizes hyper-saturated capital cities | **VIABLE (New Product Launch Mode)** |
| **Option B: Positive Driver** | $\text{DLMAI} = V + 0.08 \cdot \text{P7}$ | 0.9654 | 90.0% | Rewards established industrial clusters | **VIABLE (Supply-Chain / B2B Expansion)** |
| **Option C: Two-Axis Decoupled** | $[\mathbf{X}: \text{DLMAI}_{\text{Core}}, \mathbf{Y}: \text{Saturation}_{\text{P7}}]$ | **1.0000** | **100.0%** | **4-Quadrant Matrix (Demand vs Saturation)** | **RECOMMENDED DLMAI v3.0 ENTERPRISE** |

---

## 3. The 4-Quadrant Strategic Action Framework

```
                          HIGH PATIENT MARKET NEED (P1-P6)
                                         │
                    QUADRANT 2           │           QUADRANT 1
              "PRIME EXPANSION"          │      "BATTLEGROUND CORE"
           High Need / Low Saturation    │   High Need / High Saturation
        ---------------------------------│---------------------------------
        Strategy: Rapid field-force      │ Strategy: Differentiated specialty
        deployment, primary care brand   │ therapies, key opinion leader (KOL)
        prescriptions, pharmacy reach    │ institutional hospital penetration
                                         │
─────────────────────────────────────────┼─────────────────────────────────────────
                                         │
                    QUADRANT 4           │           QUADRANT 3
               "EMERGING WATCH"          │     "HEADQUARTERS HUB"
            Low Need / Low Saturation    │   Low Need / High Saturation
        ---------------------------------│---------------------------------
        Strategy: Lean distribution,     │ Strategy: B2B manufacturing supply,
        digital detailing, monitor       │ clinical trials, co-marketing
        socioeconomic maturation         │ partnerships
                                         │
                           LOW PATIENT MARKET NEED (P1-P6)
```

Documented in [`outputs/v3/p7_architecture_comparison.csv`](file:///e:/DMLIA-Sun%20pharma/dlmai_complete/outputs/v3/p7_architecture_comparison.csv).
